Women in STEM

Rest in Power: Jane Goodall, the Gentle Disrupter Whose Research on Chimpanzees Redefined What It Meant to Be Human

PUBLISHED 10/7/2025 by

To the public, she was a world-renowned scientist and icon. To me, she was Jane—my inspiring mentor and friend.

Goodall spoke of animals as having emotions and cultures, and in the case of chimps, communities that were almost tribal. She also named the chimps she observed, an unheard-of practice at the time, garnering ridicule from scientists who had traditionally numbered their research subjects.

Goodall was persuasive, powerful and determined, and she often advised me not to succumb to people’s criticisms. Her path to groundbreaking discoveries did not involve stepping on people or elbowing competitors aside.

An Open Letter to Rep. Kat Cammack From a Medical Doctor: It’s Abortion Bans That Make Doctors Afraid to Act, Not ‘the Radical Left’

PUBLISHED 7/10/2025 by | UPDATED 8/5/2025 at 11:19 A.M. PT

No woman may escape the cruelty of the nebulous and varying restrictions on reproductive healthcare in the post-Roe world—as Rep. Kat Cammack (R-Fla.) discovered in May 2024 when faced with a life-threatening ectopic pregnancy shortly after Florida’s six-week abortion ban took effect. Concerned by the lack of clarity in the wording of the law on the limits of intervention in pregnant patients, doctors reportedly delayed administering intramuscular methotrexate to terminate the pregnancy, out of fear of prosecution.

I’m a doctor. In this chaotic landscape, where reproductive healthcare policy and medical reality appear woefully divorced, my colleagues and I don’t know what misstep could land us in senseless litigation or with felony charges.

Rep. Cammack, your voice and your story have power. I hope you use them to reintroduce nuance and common sense to the discussion on women’s lives. There are many of us who will extend a hand across the aisle and work together with you to right some of the senseless wrongs. 

Biotech CEOs to FDA: Don’t Let Politics Override Science on Abortion Pill

PUBLISHED 7/10/2025 by

Fifty-three biotechnology industry leaders and investors representing dozens of companies and organizations issued a letter late last month advising the U.S. Food and Drug Administration: Follow the science on mifepristone, not political ideology.

The Biotech CEO Sisterhood initiated the letter, with Grace Colón as lead author and dozens of senior biotechnology leaders signed on in support. “We are urging the agency and the department to continue to follow the science,” said Colón, who warned that political interference in drug regulation undermines both public trust and the FDA’s authority.

How Reshma Saujani Makes the Invisible Work of Motherhood Impossible to Ignore

PUBLISHED 7/1/2025 by | UPDATED 7/7/2025 at 12:25 P.M. PT

Most women are taught to make motherhood look effortless. Reshma Saujani wants you to see that we were never supposed to do it alone.

In a country that still treats caregiving as a personal responsibility rather than a public good, Saujani is changing the script. Not by asking for sympathy, but by exposing the architecture of the lie—and building something better in its place.

“I come from a long line of rule-breakers,” she told me. “My parents fled a dictator. They landed in Chicago with nothing. I grew up surrounded by refugees who were just trying to make it work. That kind of survival teaches you two things: one, that struggle is constant—and two, that silence is dangerous.”

She was a rule-breaker long before she was a movement-builder—always challenging authority, always in detention. “I’ve never been good at following the script,” she said. And that’s exactly what makes her effective.

Illinois Lawmakers Pursue Creative Path to Protect Mifepristone Access—Even if FDA Revokes Approval

PUBLISHED 6/10/2025 by

While antiabortion extremists work to eliminate mifepristone from the shelves—and the FDA faces mounting antiabortion political pressure to revoke its approval—Illinois lawmakers are fighting back with a legal firewall: a first-of-its-kind bill to keep abortion pills on the market, even if the Trump administration bans them.

The Illinois General Assembly has passed HB 3637, legislation allowing clinicians to prescribe drugs removed from the FDA’s approved list—as long as the World Health Organization still recommends them. Under the bill, Illinois clinicians could continue prescribing and dispensing the abortion medication mifepristone—even if the Trump administration rolls back the FDA’s longstanding approval of the medication. The legislation now awaits the signature of Illinois Governor J.D. Pritzker.

Rest in Power: Étienne-Émile Baulieu, Abortion Pill Inventor and Women’s Rights Advocate 

PUBLISHED 6/4/2025 by

Millions of women around the world gained safety, dignity and autonomy over their bodies thanks to Étienne-Émile Baulieu. The visionary biochemist, feminist and fearless innovator—best known for developing and championing “RU 486,” now known as mifepristone—died at his Paris home on May 30 at the age of 98.

Mifepristone has saved countless lives and offered millions of women a way to end unwanted pregnancies in the privacy and comfort of their homes. Baulieu and others championed the development of mifepristone for uses beyond abortion—including for treatment of fibroids, endometriosis, postpartum depression and cancer. He supported its use in managing miscarriages and as a way to help to dilate the cervix to reduce the need for Caesarean births. His vision for mifepristone wasn’t just to end pregnancies but to protect women’s health and reduce medical intervention that too often harmed them.

He predicted in 1991: “RU-486 will make its American entrance: science, good sense, and freedom will triumph.”

And here’s his view on why there has been tremendous opposition to abortion pills from the antiabortion movement: “A method that makes the termination of pregnancy less physically traumatic for women and less risky to their health has always been rejected by pro-lifers: What they really seek is to harm and punish women.”

Outperforming Men, Undervalued Anyway: How Conservative Myths Undermine Women in Medicine

PUBLISHED 5/29/2025 by | UPDATED 9/15/2025 at 10:00 A.M. PT

Medical literature extensively documents differences in practice by a physician’s gender. Women are more likely to practice evidence-based medicine and adhere to clinical guidelines. Nationally, women outpace men in both college and medical school enrollment. In medical training, women outperform their male peers on clinical assessments and are more likely to attain an honors degree.

Therefore, the merit-based hiring practices that the Trump administration vociferously demands should logically reflect these data. Yet, in 2022, women accounted for 38 percent of active physicians in the U.S., up from 26 percent in 2004. 

Might this indicate that men, not women, are the “diversity hires” of medicine? 

Trump’s STEM Funding Attacks Will Undo Decades of Gender Equity Progress

PUBLISHED 5/21/2025 by

Trump’s aversion to science and research is well-known. So, it is not surprising that the country’s top scientific research agencies, including the National Science Foundation (NSF) and the National Institutes of Health (NIH), were among those targeted under his anti-DEI executive orders and reckless federal funding cuts.

Labeling all equality-focused initiatives as “wokeness,” “discrimination” and “wasteful spending” is really about putting up new barriers for women and minorities.

Why Democracy Needs Data—and What Happens When It Vanishes

PUBLISHED 5/20/2025 by and

In the first few months of Donald Trump’s return to the presidency, one thing has become crystal clear: The war on gender and racial equity is being waged in a new arena—on the battleground of data.

This fight isn’t waged with tweets or soundbites. It’s carried out through budget cuts, shuttered research programs and disappearing federal surveys. It’s a quiet but devastating assault on the tools we rely on to tell the truth—and to hold those in power accountable. And the message is chilling: If we can’t measure inequality, maybe we can pretend it doesn’t exist.

When race is stripped from maternal health reports, we overlook the crisis facing Black mothers. When LGBTQ+ identity is erased from youth surveys, we lose critical insight into mental health and safety. When disability status is omitted from labor market data, inequities in access and pay go unaddressed.

We need a renewed federal commitment to the research infrastructure that allows us to see and solve inequality—not ignore it.